Recruiting
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Recruiting
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270
The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
How long will I be in the trial?
Your participation may continue for as long as you and your study doctor feel that you are benefiting from the study treatment.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participants must NOT
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.
Trial Summary
Conditions the trial is for
Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
What the trial is testing?
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib
Could I receive a Placebo?
no
Enrollment Goal
245
Trial Dates
September 2016 - September 2021
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participants must NOT
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.
Trial Summary
Conditions the trial is for
Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
What the trial is testing?
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib
Could I receive a Placebo?
no
Enrollment Goal
245
Trial Dates
September 2016 - September 2021
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
